GW Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference on 12 March
March 05 2018 - 12:36PM
GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the
Group), a biopharmaceutical company focused on discovering,
developing and commercializing novel therapeutics from its
proprietary cannabinoid product platform, announced that Justin
Gover, GW’s Chief Executive Officer, will present at the Cowen and
Company 38th Annual Health Care Conference on Monday, March 12,
2018, at 2:50 p.m. (EDT) at the Boston Marriott Copley Place in
Boston, M.A.
A live audio webcast of the presentation will be
available through GW’s corporate website in the investor relations
section from the investor’s calendar of events page at
www.gwpharm.com. A replay will be available soon
after the live presentation.
About GW Pharmaceuticals plc and
Greenwich Biosciences
Founded in 1998, GW is a biopharmaceutical
company focused on discovering, developing and commercializing
novel therapeutics from its proprietary cannabinoid product
platform in a broad range of disease areas. GW, along with its U.S.
subsidiary Greenwich Biosciences, is advancing an orphan drug
program in the field of childhood-onset epilepsy with a focus on
Epidiolex (cannabidiol), for which GW has submitted regulatory
applications in the U.S. and Europe for the adjunctive treatment of
Lennox-Gastaut syndrome and Dravet syndrome. The Company continues
to evaluate Epidiolex in additional rare epilepsy conditions and
currently has ongoing clinical trials in Tuberous Sclerosis Complex
and Infantile Spasms. GW commercialized the world’s first
plant-derived cannabinoid prescription drug, Sativex® (nabiximols),
which is approved for the treatment of spasticity due to multiple
sclerosis in numerous countries outside the United States and for
which the company is now planning a US Phase 3 trial. The Company
has a deep pipeline of additional cannabinoid product candidates
which includes compounds in Phase 1 and 2 trials for epilepsy,
gliobastoma, and schizophrenia. For further information, please
visit www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc |
|
|
Stephen Schultz, VP Investor Relations (U.S.) |
|
917 280 2424 / 401 500 6570 |
|
|
|
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Apr 2023 to Apr 2024